Viking Therapeutics, Inc. - Common Stock (VKTX)
25.91
-0.13 (-0.50%)
NASDAQ · Last Trade: Sep 19th, 3:00 PM EDT
Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.
Via The Motley Fool · September 19, 2025
Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential
Via MarketBeat · September 17, 2025
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for 2025, sending ripples through the global anti-obesity drug market. Despite robust initial half-year performance and the surging demand for weight-loss medications, the Danish giant
Via MarketMinute · September 15, 2025
Viking Short Interest Hits 5-Year High After Weight-Loss Drug Stumble, But Retail Clings To Bullish Mood For Nowstocktwits.com
Via Stocktwits · August 24, 2025
One of them is already a leader in the market for weight management drugs, and the other could join this field.
Via The Motley Fool · September 11, 2025
Via Benzinga · September 9, 2025
The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.
Via The Motley Fool · September 7, 2025
Market analysts and financial commentators provide crucial guidance in the volatile investment landscape. Cramer says no to VKTX, but expects PLTR to go up.
Via Benzinga · September 5, 2025
Viking aims to enter the billion-dollar weight loss drug market.
Via The Motley Fool · September 5, 2025
Both companies have made significant progress in recent years.
Via The Motley Fool · September 4, 2025
There are new ways to tackle weight loss, but the stocks leading the way are lagging.
Via The Motley Fool · September 3, 2025
Investment bank analysts up and down Wall Street are pounding the table on these stocks.
Via The Motley Fool · August 29, 2025
The company's obesity drug could have more potential than originally believed.
Via The Motley Fool · August 28, 2025
Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock.
Via The Motley Fool · August 27, 2025
The market for weight loss treatments is growing significantly and is forecast to continue increasing for several years.
Via The Motley Fool · August 27, 2025
Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test.
Via Investor's Business Daily · August 26, 2025

Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum.
Via The Motley Fool · August 26, 2025

These companies aren't performing as badly as their stock-market performances this year suggest.
Via The Motley Fool · August 24, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · August 23, 2025
Via Benzinga · August 22, 2025
The phase 2 trial results for its key drug didn't pan out quite as planned.
Via The Motley Fool · August 22, 2025
A disappointing result for its oral obesity candidate hammered the stock price.
Via The Motley Fool · August 21, 2025
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing.
Via The Motley Fool · August 20, 2025
The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (NYSE: PLTR) and Viking Therapeutics (NASDAQ: VKTX), come under intense investor scrutiny. Despite a year of impressive gains for Palantir, concerns over its valuation have led
Via MarketMinute · August 20, 2025
Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior.
Via Benzinga · August 20, 2025